Rosalind Rei has a background in science communication and business journalism. Before joining Generics Bulletin in 2022, she worked as a freelance writer and researcher covering sustainability, biotech, biomaterials, climate science, and carbon finance. She has also written and produced episodes on the history of science for the Harvard-based podcast Ministry of Ideas.
She holds a master’s in the history and philosophy of science and takes keen interests in political economy, ecology, and environment.
Latest From Rosalind Rei
Gloomy First Half Results For Mayne
Revenue falls 33% over the half year for the ailing Australian pharmaceutical as it pivots from generics to the branded market
Chemiphar Profit Slumps 82.5% In Q3
Plummeting sales and profit following government price regulations pushes Chemiphar to target international expansion
Teva To Hand Florida $6.73m Over Price-Fixing Allegations
Teva has agreed to settle Florida’s price-fixing allegations for $6.73m, its fifth and largest state settlement sum so far. Payouts to further states are expected.
FDA Begins Reviewing Henlius’ Trastuzumab
The US FDA has accepted a BLA for Henlius’ trastuzumab biosimilar candidate HLX02, marking another step in the Chinese company’s push for the US oncology market
Torrent’s Brazil Growth Surges 36% In Q3
Torrent’s quarterly revenues were up by 18% to INR24.9bn in Q3 FY2023. Branded generics and the Brazilian market did much of the heavy lifting.
New Insulin Manufacturer For Civica
Ypsomed AG will manufacture insulin dosing injector pens for non-profit Civica. Civica has also paired up with AmerisourceBergen for generics supply chain support across the US.